

Q²
4. (Amended) The preparation according to claim 1,
characterized in that the excipient contains a transfer medium
transporting the active ingredient.

6. (Amended) The preparation according to claim 1,
characterized in that it is present in the form of a formula for
topical application.

Q³
7. (Amended) The preparation according to claim 1,
characterized in that it is present in the form of an injection
formula.

8. (Amended) The preparation according to claim 1,
characterized in that it is intended for the pigmentation or de-
pigmentation of skin or hair.

Q⁴
10. (Amended) The use of the protein DCoH, the DNA and/or
RNA for the coding of said protein, or DCoH antibodies or DCoH
antiserum, as active ingredient for producing a preparation
according to claim 1 for the treatment of pigmentation disorders
of the human or animal body.

A marked-up version of the claims is shown as Exhibit A.